랩포트 테라퓨틱스(RAPP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $40.85 (-2.62%), 시가총액 $1.76B, 52주 최저~최고 $8.27 ~ $39.93.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the tr
랩포트 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
랩포트 테라퓨틱스의 현재 주가는 $40.85 (-2.62%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
랩포트 테라퓨틱스의 시가총액은 약 $1.76B입니다.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering fro